Rauwolfia (Indian Snakeroot) for Blood Pressure Regulation

Research suggests that Rauwolfia serpentina and its primary alkaloid reserpine have a well-documented history of effectiveness in blood pressure regulation, supported by a notably consistent body of evidence spanning several decades. The evidence base includes a Cochrane meta-analysis quantifying dose-related reductions in blood pressure, an RCT meta-analysis demonstrating statistically significant systolic blood pressure reductions with reserpine monotherapy versus placebo, multiple clinical and pharmacological reviews, Ayurvedic medicine literature, and regulatory recognition in the form of FDA approval for reserpine as an antihypertensive agent. Studies indicate that reserpine's mechanism involves interference with catecholamine storage and release, and historical reviews place it among the earliest pharmaceutical antihypertensives to enter clinical practice, with some guidelines recommending it as a second-line option for blood pressure control. It is worth noting that much of the supporting literature consists of reviews and older studies rather than large modern randomized trials, and contemporary clinical use has declined in favor of newer drug classes, meaning readers should weigh the historical depth of evidence against the relatively limited presence of recent high-quality primary research.